<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790812</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-DB-20-0118</org_study_id>
    <nct_id>NCT04790812</nct_id>
  </id_info>
  <brief_title>Preemptive Analgesia With Celecoxib for Acute Dental Pain Management</brief_title>
  <official_title>Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect on postoperative pain of a single agent&#xD;
      nonsteroidal anti-inflammatory drug (NSAID) [celecoxib plus placebo] to an NSAID combination&#xD;
      [celecoxib plus acetaminophen] administered preemptively to patients prior to impacted third&#xD;
      molar surgery. .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, placebo-controlled, prospective clinical trial is designed to&#xD;
      compare the postoperative pain reduction of a single agent nonsteroidal anti-inflammatory&#xD;
      drug (NSAID) and NSAID combination regimen administered preemptively. Subjects will be given&#xD;
      a single oral dose of a cyclooxygenase-2 (COX-2) selective inhibitor (celecoxib 200mg), or&#xD;
      celecoxib 200 mg in combination with acetaminophen (APAP 1000 mg) 30 to 60 minutes prior to&#xD;
      the procedure. Oral surgery involving at least one impacted mandibular third molar will be&#xD;
      performed using a combination of intravenous sedation and local anesthesia following UTHealth&#xD;
      School of Dentistry (UTSD) surgical protocol. All subjects will be released with identical&#xD;
      postoperative instructions and prescriptions for pain management. Nonopioid pain management&#xD;
      will be prescribed as follows: 600mg ibuprofen with 500 mg APAP every 6 hours for the first 3&#xD;
      days, then as needed for pain. Subjects will be asked to document medication consumption,&#xD;
      postoperative pain and complications for the following 3 days using a Qualtrics survey. An&#xD;
      oral and maxillofacial surgery resident or faculty on call can offer emergency intervention&#xD;
      with prescription of an opioid analgesic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">April 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, placebo-controlled, prospective clinical trial. Subjects will be given a single oral dose of celecoxib 200 mg with placebo (Group 1), or celecoxib 200 mg in combination with acetaminophen 1000 mg (Group 2) 30 to 60 minutes prior to the dental procedure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Patient regimen randomization will be achieved by use of a random number generator. The care provider or clinic faculty/nurse will blindly administer the regimen to the patient prior to procedure. A placebo capsule will be used to mimic the acetaminophen capsule to maintain blinding of care provider and patient. Preemptive medications will be dispensed in disposable containers prior to the start of daily operations. The research member tasked with dispensing will not be involved with the administration of medications to patients on the day of surgery. The PI and other members of the research team will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>3 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>8 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>12 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>18 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>24 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>36 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>48 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain as assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>72 hours after procedure</time_frame>
    <description>Psychometric response scale to be included in a questionnaire to evaluate pain intensity. A 0-10 pain scale will be used with visual &quot;Faces&quot; to correspond with the numerical values, with 10 indicating worse pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>3 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>8 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>12 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>18 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>24 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>36 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>48 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as assessed by a Categorical Descriptive Questionnaire</measure>
    <time_frame>72 hours after procedure</time_frame>
    <description>A questionnaire will ask whether the study participant's pain is dull, aching, throbbing, pulsing, stinging, and/or stabbing. Results will be reported categorically as the number of participants who experience the pain descriptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Receive an Emergency Analgesic Intervention</measure>
    <time_frame>Any time during the 72 hours after procedure</time_frame>
    <description>Emergency interventions are medications or treatments for postoperative pain not prescribed in study, including medications taken other than those prescribed for after the surgery, calling for prescription of medications other than those prescribed for after the surgery, and seeking outside dental/medical attention (for example: private practice or hospital).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Celecoxib plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of celecoxib 200 mg with placebo 30 to 60 minutes prior to the dental procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib plus Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose of celecoxib 200 mg in combination with acetaminophen 1000 mg 30 to 60 minutes prior to the dental procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).</description>
    <arm_group_label>Celecoxib plus Acetaminophen</arm_group_label>
    <arm_group_label>Celecoxib plus Placebo</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>COX-2 selective inhibitor, COX-2 selective NSAID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.</description>
    <arm_group_label>Celecoxib plus Acetaminophen</arm_group_label>
    <other_name>Tylenol, APAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.</description>
    <arm_group_label>Celecoxib plus Placebo</arm_group_label>
    <other_name>Inactive substance, inert substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status classification 1 or 2&#xD;
&#xD;
          -  at least 1 impacted mandibular third molar planned for extraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA 3 or higher for physical status classification&#xD;
&#xD;
          -  severe pericoronitis associated with third molar to be extracted&#xD;
&#xD;
          -  any known allergies to NSAIDs, aspirin, acetaminophen, sulfa drugs&#xD;
&#xD;
          -  history of cardiovascular or cerebrovascular disease&#xD;
&#xD;
          -  hepatic disease or impairment&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry D Gilbert, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas School of Dentistry at Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Auco Dang</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas School of Dentistry at Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline K Cutbirth, BS</last_name>
    <phone>713-486-4315</phone>
    <email>Caroline.K.Cutbirth@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harry D Gilbert, DDS</last_name>
    <phone>713-486-4315</phone>
    <email>Harry.D.Gilbert@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas School of Dentistry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert D Spears, PhD, MS</last_name>
      <phone>713-486-4013</phone>
      <email>Robert.D.Spears@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Auco Dang, Director</last_name>
      <phone>713-486-4258</phone>
      <email>Auco.Dang@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Harry D Gilbert, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Casandra L Barnes, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur H Jeske, DMD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan L Myers, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberly S Ruona, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/drugoverdose/epidemic/index.html</url>
    <description>Background information reference to The Centers for Disease Control and Prevention (CDC) on statistics relevant to the opioid epidemic supporting the need for other pain modalities.</description>
  </link>
  <reference>
    <citation>Bauer HC, Duarte FL, Horliana AC, Tortamano IP, Perez FE, Simone JL, Jorge WA. Assessment of preemptive analgesia with ibuprofen coadministered or not with dexamethasone in third molar surgery: a randomized double-blind controlled clinical trial. Oral Maxillofac Surg. 2013 Sep;17(3):165-71. doi: 10.1007/s10006-012-0360-7. Epub 2012 Sep 5.</citation>
    <PMID>22949122</PMID>
  </reference>
  <reference>
    <citation>Cicconetti A, Bartoli A, Ripari F, Ripari A. COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Feb;97(2):139-46.</citation>
    <PMID>14970772</PMID>
  </reference>
  <reference>
    <citation>Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb.</citation>
    <PMID>22336956</PMID>
  </reference>
  <reference>
    <citation>Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. Review.</citation>
    <PMID>11566042</PMID>
  </reference>
  <reference>
    <citation>Jung YS, Kim MK, Um YJ, Park HS, Lee EW, Kang JW. The effects on postoperative oral surgery pain by varying NSAID administration times: comparison on effect of preemptive analgesia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Nov;100(5):559-63.</citation>
    <PMID>16243240</PMID>
  </reference>
  <reference>
    <citation>May N, Epstein J, Osborne B. Selective COX-2 inhibitors: a review of their therapeutic potential and safety in dentistry. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Oct;92(4):399-405. Review.</citation>
    <PMID>11598574</PMID>
  </reference>
  <reference>
    <citation>Nissen SE, Yeomans ND, Solomon DH, LÃ¼scher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial Investigators. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.</citation>
    <PMID>27959716</PMID>
  </reference>
  <reference>
    <citation>Ong CK, Lirk P, Seymour RA, Jenkins BJ. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. Anesth Analg. 2005 Mar;100(3):757-773. doi: 10.1213/01.ANE.0000144428.98767.0E.</citation>
    <PMID>15728066</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Harry Gilbert, DDS</investigator_full_name>
    <investigator_title>DDS, Professor - Oral and Maxillofacial Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

